Although targeting PRLR with chemotherapy may cause complications with pregnancies and lactation, these factors pose little risk regarding most pancreatic cancer patients, due to the average age of diagnosis occurring over the age of 71 [74]. The gene discussed is PRLR; the disease is familial pancreatic carcinoma.